Groundbreaking Pancreatic Cancer Drug Shows Promise in Lung Cancer
(MedPage Today) -- The landmark oral RAS inhibitor daraxonrasib (Rasonque) showed efficacy in previously treated patients with metastatic RAS-mutant non-small cell lung cancer (NSCLC) in a phase I/II trial. Among 136 patients treated with daraxonrasib...
DeafMonitor aggregates Deaf-community news and credits every story to its original publisher. This story was reported by MedPage Today — ENT.
Read the full story at MedPage Today — ENT
Read the full story at MedPage Today — ENT